Glutamatergic transmission in schizophrenia: from basic research to clinical practice
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: The past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics. RECENT FINDINGS: We review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and humans. SUMMARY: Although evidence continues to accumulate in support of glutamate hypotheses, further research continues to be required and interactions with other key systems need to be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Self-citationA meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510 · cited 1×
“Although D-cycloserine does not appear to be effective as an adjunctive treatment in schizophrenia, it has been successfully used to enhance learning and behavioral therapies in anxiety disorders [30].”
BackgroundNeuronal correlates of cognitive reappraisal in borderline patients with affective instability
Schulze, L., Domes, G., Krüger, A., Berger, C., Fleischer, M., Prehn, K., Schmahl, C., Grossmann, A., Hauenstein, K., & Herpertz, S. C. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.10.025 · Cited by 266
Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218dcd5 · Cited by 256
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180
D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
Gottlieb, J. D., Cather, C., Shanahan, M., Creedon, T., Macklin, E. A., & Goff, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.029 · Cited by 73 · cited 1×
“In a proof of concept study [32], an NMDA agonist dose of D-cycloserine was combined with a cognitive behavioral therapy (CBT) targeting delusions.”
Background
Cited by
Wang, M., Yang, Y., Wang, C.-J., Gamo, N. J., Jin, L. E., Mazer, J. A., Morrison, J. H., Wang, X.-J., & Arnsten, A. F. T. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.032 · Cited by 489
“Recent findings indicate that impaired cognitive abilities in patients with schizophrenia are associated with reduced NMDAR glutamate signaling (Bustillo et al., 2011), rather than the hyperglutamate signaling that has been the focus of recent theories (reviewed in Kantrowitz and Javitt, 2012).”
BackgroundImmunoneuropsychiatry — novel perspectives on brain disorders
Pape, K., Tamouza, R., Leboyer, M., & Zipp, F. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0174-4 · Cited by 458
Auditory dysfunction in schizophrenia: integrating clinical and basic features
Javitt, D. C., & Sweet, R. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4002 · Cited by 367
Self-citationSteullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., & Do, K. Q. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.021 · Cited by 262
“…disturbance of glutamatergic neurotransmission in the form of hypofunction of NMDA receptors (NMDARs) (Krystal et al., 1994; Coyle et al., 2012; Kantrowitz and Javitt, 2012; Steiner et al., 2013), neuroinflammation (Saetre et al., 2007; Potvin et al., 2008; van Berckel et al., 2008; Meyer,…”
Influentialde Bartolomeis, A., Buonaguro, E. F., & Iasevoli, F. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2921-8 · Cited by 89
“Beyond the complexity of the disease, dysfunctions of dopamine, glutamate and serotonin systems are considered crucial in the pathophysiology of schizophrenia (Marek 2007; Kantrowitz and Javitt 2012).”
Background
Metadata
- Authors
- Kantrowitz, J., & Javitt, D. C.
- Venue
- Current Opinion in Psychiatry
- Published
- 2012-03
- Volume
- 25
- Issue
- 2
- Pages
- 96-102
- ISSN
- 0951-7367 (ISSN-L)
- OpenAlex
- W2334576434
- Cited by
- 155
- References
- 6
- FWCI
- 14.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.